Amgen vs Novartis

Amgen (AMGN), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novartis is worth $301.5B on the stock market and Amgen $248.1B: Novartis is valued at 22% more. Amgen trades at 26.6 times earnings and Novartis at 30.5; operating margins in their latest fiscal years were 24.7% and 32.4%. Over the past year Amgen's share price has moved +34.4% and Novartis's +25.1%.

Key facts

Amgen market value
$248.1B
Novartis market value
$301.5B
Amgen P/E
26.6
Novartis P/E
30.5
Amgen revenue
$36.8BFY to 2025-12-31
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
3

Market values as of .

Amgen vs Novartis: every measure side by side
Measure Amgen Novartis
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$248.1Blower$301.5Bhigher
Revenue$36.8Blower$54.5Bhigher
Earnings$7.7Blower$14Bhigher
Employees31,500lower75,267higher
Total assets$90.6Blower$110.9Bhigher
Valuation
P/E26.6lower30.5higher
P/S6.8higher5.5lower
P/B17.3—
Dividend yield2.15%—
Profitability
Operating margin24.7%lower32.4%higher
Balance sheet
Net assets$8.7Blower$46.1Bhigher
Total liabilities$81.9Bhigher$64.4Blower
Total debt$54.6Bhigher$28.7Blower
Cash on hand$9.1Blower$11.4Bhigher
Price change
Today-0.80%lower-0.35%higher
1 year+34.4%higher+25.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Amgen / Novartis). Who owns AMGN · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, Amgen or Novartis?

By market value, Novartis is the larger: $301.5B against $248.1B for Amgen. By revenue in its latest fiscal year, Novartis is the larger: $54.5B against $36.8B for Amgen.

Which has the higher P/E ratio?

Novartis: 30.5, against 26.6 for Amgen. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Novartis: 32.4%, against 24.7% for Amgen. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Amgen: $54.6B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Amgen and Novartis?

In their latest 13F filings, Primecap team, Ken Fisher and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Amgen vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/amgn-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.